Anhui Shixing Chemical Co., Ltd.

Vorinostat is a novel molecularly targeted antitumor drug that arrests cell cycle arrest and/or apoptosis by inhibiting histone deacetylase (HDAC). It is the first HDAC inhibitor approved by the US FDA for the treatment of cutaneous T-cell lymphoma (CTCL) with significant skin invasion, progression, resistance or relapse after two systemic treatment regimens.

On October 6, 2006, the US Food and Drug Administration (FDA) approved vorinostat as a new drug for the treatment of skin cancer. This drug is the world's first new anticancer drug that inhibits histone deacetylase developed by Merck. It is used to treat cutaneous T-cell lymphoma (CTCL). It is approved by the FDA for other medical treatments or treatments. After still can not cure, or worsen, or metastatic skin T lymphoma in repeated cases. A large number of experimental studies and clinical results have shown that vorinostat has a good effect on a variety of tumors, and has a significant synergistic effect with other oncology drugs. At present, the treatment of other tumors continues to deepen, and these results indicate that vorinostat has a broad Market prospects.